Changes in Skin Autoflouresence Following Weight Loss and Maintenance Using Liraglutide in Knee Osteoarthritis

NCT02910570 on ClinicalTrials.gov · last registry update 2019-03-25

An unusually large phase 4: 150 participants, more than double the 75 typical for the stage. The sponsor logged completion for February 2019. Primary outcome, as filed: Change in advanced glycation end products in the skin. liraglutide is approved in the US, but not for osteoarthritis — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: COMPLETED
Phase: P4
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: Parker Research Institute
Sponsor type: Other
Enrollment: 150
Started: 2016-11
Primary completion: 2019-02 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in advanced glycation end products in the skin

Conditions studied

Osteoarthritis, Knee

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.